2024 Q2 Form 10-Q Financial Statement
#000168316824003690 Filed on May 20, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $43.00K | $89.00K | $150.0K |
| YoY Change | -44.38% | -11.76% | |
| % of Gross Profit | |||
| Research & Development | $126.0K | -$48.00K | |
| YoY Change | -45.92% | -126.82% | |
| % of Gross Profit | |||
| Depreciation & Amortization | $13.00K | $21.00K | |
| YoY Change | 30.0% | 950.0% | |
| % of Gross Profit | |||
| Operating Expenses | $43.00K | $126.0K | $102.0K |
| YoY Change | -45.92% | -70.77% | |
| Operating Profit | -$241.0K | -$215.0K | |
| YoY Change | 354.72% | -45.29% | |
| Interest Expense | $203.0K | -$152.0K | |
| YoY Change | 163.64% | -58.13% | |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$2.548M | $203.0K | |
| YoY Change | 169.06% | 163.64% | |
| Pretax Income | -$12.00K | -$254.0K | |
| YoY Change | -96.2% | -64.33% | |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$2.694M | $70.00K | -$224.0K |
| YoY Change | 170.48% | -137.63% | -64.5% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.66 | $0.02 | |
| Diluted Earnings Per Share | -$0.66 | $0.02 | -$0.05 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 4.216M shares | 4.216M shares | 4.216M shares |
| Diluted Shares Outstanding | 4.216M shares | 4.216M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $579.0K | $813.0K | |
| YoY Change | -58.64% | 0.37% | |
| Cash & Equivalents | $178.0K | $141.0K | $176.0K |
| Short-Term Investments | $438.0K | $637.0K | |
| Other Short-Term Assets | $316.0K | $290.0K | $313.0K |
| YoY Change | 544.9% | 286.67% | 268.24% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | $313.0K | ||
| Total Short-Term Assets | $516.0K | $880.0K | $1.137M |
| YoY Change | -65.42% | -40.58% | 26.19% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $487.0K | $358.0K | $256.0K |
| YoY Change | 97.17% | 49.79% | 16.89% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $494.0K | $369.0K | $271.0K |
| YoY Change | 83.64% | 39.25% | 8.84% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $516.0K | $880.0K | $1.137M |
| Total Long-Term Assets | $494.0K | $369.0K | $271.0K |
| Total Assets | $1.010M | $1.249M | $1.408M |
| YoY Change | -42.65% | -28.47% | 22.43% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $130.0K | $90.00K | $46.00K |
| YoY Change | 261.11% | 114.29% | -16.36% |
| Accrued Expenses | $6.000K | $13.00K | |
| YoY Change | -80.0% | -59.38% | |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $2.116M | $2.074M | |
| YoY Change | 8.4% | -3.31% | |
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $2.974M | $3.130M | |
| YoY Change | -9.41% | -15.84% | |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.974M | $3.130M | |
| Total Long-Term Liabilities | $0.00 | $0.00 | |
| Total Liabilities | $5.518M | $2.974M | $3.130M |
| YoY Change | 29.8% | -9.41% | -15.84% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$25.55M | -$22.86M | -$22.93M |
| YoY Change | 7.42% | 0.3% | 1.43% |
| Common Stock | $20.65M | $20.65M | $20.64M |
| YoY Change | 516225.0% | 516150.0% | 516000.0% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$4.899M | -$2.208M | -$2.284M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $1.010M | $1.249M | $1.408M |
| YoY Change | -42.65% | -28.47% | 22.43% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$2.694M | $70.00K | -$224.0K |
| YoY Change | 170.48% | -137.63% | -64.5% |
| Depreciation, Depletion And Amortization | $13.00K | $21.00K | |
| YoY Change | 30.0% | 950.0% | |
| Cash From Operating Activities | -$116.0K | -$302.0K | |
| YoY Change | -72.18% | 19.37% | |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $113.0K | $31.00K | |
| YoY Change | 334.62% | 342.86% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $199.0K | $84.00K | |
| YoY Change | 1580.0% | ||
| Cash From Investing Activities | $86.00K | $53.00K | |
| YoY Change | -430.77% | -2750.0% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -$5.000K | 0.000 | |
| YoY Change | -100.48% | -100.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -$116.0K | -302.0K | |
| Cash From Investing Activities | $86.00K | 53.00K | |
| Cash From Financing Activities | -$5.000K | 0.000 | |
| Net Change In Cash | -$35.00K | -249.0K | |
| YoY Change | -105.93% | -140.23% | |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$116.0K | -$302.0K | |
| Capital Expenditures | $113.0K | $31.00K | |
| Free Cash Flow | -$229.0K | -$333.0K | |
| YoY Change | -48.31% | 28.08% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
| CY2024Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2024Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2023Q1 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
usd | |
| CY2024Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2024Q1 | dei |
Entity File Number
EntityFileNumber
|
333-208814 | |
| CY2024Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
SATIVUS TECH CORP. | |
| CY2024Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
| CY2024Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
47-2847446 | |
| CY2024Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
#3 Bethesda Metro Center | |
| CY2024Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
#700 | |
| CY2024Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Bethesda | |
| CY2024Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MD | |
| CY2024Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
06880 | |
| CY2024Q1 | dei |
City Area Code
CityAreaCode
|
800 | |
| CY2024Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
608-6432 | |
| CY2024Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2024Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
No | |
| CY2024Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2024Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2024Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
| CY2024Q1 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
| CY2024Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
4215571 | shares |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
141000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
176000 | usd |
| CY2024Q1 | us-gaap |
Deposit Assets
DepositAssets
|
438000 | usd |
| CY2023Q4 | us-gaap |
Deposit Assets
DepositAssets
|
637000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
11000 | usd |
| CY2023Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
11000 | usd |
| CY2024Q1 | us-gaap |
Assets Current
AssetsCurrent
|
880000 | usd |
| CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1137000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
11000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
15000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
358000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
256000 | usd |
| CY2024Q1 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
369000 | usd |
| CY2023Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
271000 | usd |
| CY2024Q1 | us-gaap |
Assets
Assets
|
1249000 | usd |
| CY2023Q4 | us-gaap |
Assets
Assets
|
1408000 | usd |
| CY2024Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
90000 | usd |
| CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
46000 | usd |
| CY2024Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
129000 | usd |
| CY2023Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
112000 | usd |
| CY2024Q1 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
2116000 | usd |
| CY2023Q4 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
2074000 | usd |
| CY2024Q1 | satt |
Fair Value Of Convertible Component In Convertible Loans
FairValueOfConvertibleComponentInConvertibleLoans
|
633000 | usd |
| CY2023Q4 | satt |
Fair Value Of Convertible Component In Convertible Loans
FairValueOfConvertibleComponentInConvertibleLoans
|
885000 | usd |
| CY2024Q1 | us-gaap |
Other Short Term Borrowings
OtherShortTermBorrowings
|
6000 | usd |
| CY2023Q4 | us-gaap |
Other Short Term Borrowings
OtherShortTermBorrowings
|
13000 | usd |
| CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
2974000 | usd |
| CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
3130000 | usd |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
4215571 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
4215571 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
4215571 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
4215571 | shares |
| CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | usd |
| CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | usd |
| CY2024Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
20646000 | usd |
| CY2023Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
20640000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-22858000 | usd |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-22928000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2208000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2284000 | usd |
| CY2024Q1 | us-gaap |
Minority Interest
MinorityInterest
|
483000 | usd |
| CY2023Q4 | us-gaap |
Minority Interest
MinorityInterest
|
562000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-1725000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-1722000 | usd |
| CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1249000 | usd |
| CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1408000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
126000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
233000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
89000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
160000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-215000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-393000 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
203000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
77000 | usd |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-12000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-316000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-82000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-130000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
70000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-186000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.02 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.02 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.04 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.04 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
4215571 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
4215571 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
4215571 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
4215571 | shares |
| CY2023Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-1722000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
9000 | usd |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-12000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-1725000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-2569000 | usd |
| CY2023Q1 | satt |
Share Based Compensation To Noncontrolling Parties
ShareBasedCompensationToNoncontrollingParties
|
39000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
1274000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-316000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-1537000 | usd |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-12000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-316000 | usd |
| CY2024Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
13000 | usd |
| CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
10000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
74000 | usd |
| CY2024Q1 | satt |
Financial Expenses Related To Convertible Loans And Warrants
FinancialExpensesRelatedToConvertibleLoansAndWarrants
|
42000 | usd |
| CY2023Q1 | satt |
Financial Expenses Related To Convertible Loans And Warrants
FinancialExpensesRelatedToConvertibleLoansAndWarrants
|
45000 | usd |
| CY2024Q1 | satt |
Change In Fair Value Of Convertible Component In Convertible Loans
ChangeInFairValueOfConvertibleComponentInConvertibleLoans
|
-252000 | usd |
| CY2023Q1 | satt |
Change In Fair Value Of Convertible Component In Convertible Loans
ChangeInFairValueOfConvertibleComponentInConvertibleLoans
|
-141000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-23000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-10000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
17000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-13000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
|
44000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
|
-86000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-116000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-417000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
113000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
26000 | usd |
| CY2024Q1 | satt |
Decrease Increase In Restricted Cash
DecreaseIncreaseInRestrictedCash
|
-0 | usd |
| CY2023Q1 | satt |
Decrease Increase In Restricted Cash
DecreaseIncreaseInRestrictedCash
|
-0 | usd |
| CY2024Q1 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-199000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
86000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-26000 | usd |
| CY2024Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
-0 | usd |
| CY2023Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
114000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
5000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
5000 | usd |
| CY2024Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
-0 | usd |
| CY2023Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
121000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
1273000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-5000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1033000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-35000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
590000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
176000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
810000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
141000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1400000 | usd |
| CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
0 | usd |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
121000 | usd |
| CY2024Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<p id="xdx_80C_eus-gaap--BasisOfAccounting_zFa8nt2tOiv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td> <td style="width: 92%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_820_z66IWZ09H8e8">GENERAL</span></span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SATIVUS TECH CORP. (formerly SEEDO CORP.) (the “Company”, “Our” or “We”) was formed on January 16, 2015, under the laws of the State of Delaware. Prior to July 2020, we were involved in producing a plant growing device managed and controlled by an artificial intelligent algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant, while providing optimal conditions to assure premium quality produce year-round. However, due to financial and operational difficulties and during 2020, we ceased these operations and on July 19, 2020, the Company formed a new wholly-owned subsidiary in Israel, Hachevra Legiduley Pkaot Beisrael Ltd. (the “New Subsidiary”), to develop a fully automated and remotely managed system for growing saffron and other vegetables. On November 5, 2020, the New Subsidiary changed its name to Saffron-Tech Ltd. (or “Saffron Tech”). As of the date of this report, and following various financings in Saffron Tech, the Company owns 54% of Saffron Tech.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Company, through Saffron Tech, is focusing on its in-house research and development of agriculture technology products, among others, in the fields of exotic plants and mushrooms. Saffron Tech plans to roll out its proof of concept in the coming months. This technology will provide turnkey automated growing containers for high-quality, high-yield saffron all year round. The Company is in advanced stages of developing and testing a fully automated and remotely managed system for growing high-quality, high-yield saffron anywhere and anytime.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">It is also environmentally friendly, using economic levels of water, space, fertilizer, and energy. Accounting to the Company’s calculations, we believe that the controlled indoor growing area will produce ten times more yield compared to the same land area using traditional methods. The sealed environment eliminates the need for harmful pesticides and herbicides, producing a clean and safe product that is easy to control from anywhere. The Company’s solution is easily scalable and pre-designed to quickly grow operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Saffron is used in many industries, such as the food industry, particularly by famous chefs and Michelin starred restaurants, the natural cosmetics industry and the food supplements industry and as a dye in the textile industry. Medicinal claims as an anti-depressant, antioxidant, and antiseptic are constantly increasing.</p> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit in the total amount of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240331_zcHwpqN3XM3l" title="Accumulated deficit">22,858</span> as of March 31, 2024, the Company has negative operating cash flow in the total amount of $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20240331_z18d1qO3b1Bg" title="Negative operating cash flow amount">116</span> for the three months ended March 31, 2024, further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, and future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company requires more funds than anticipated during the next 12 months or in later periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The consolidated financial statements for the three months ended March 31, 2024, do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.</p> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> | |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-22858000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-116000 | usd |
| CY2024Q1 | us-gaap |
Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
|
0 | usd |
| CY2024Q1 | us-gaap |
Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
|
89000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
0 | usd |
| CY2024Q1 | satt |
Related Party Expense
RelatedPartyExpense
|
89000 | usd |
| CY2024Q1 | satt |
Due To Related Party
DueToRelatedParty
|
-158000 | usd |
| CY2023Q1 | us-gaap |
Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
|
0 | usd |
| CY2023Q1 | us-gaap |
Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
|
63000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
0 | usd |
| CY2023Q1 | satt |
Related Party Expense
RelatedPartyExpense
|
63000 | usd |
| CY2023Q1 | satt |
Due To Related Party
DueToRelatedParty
|
-125000 | usd |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
4215571 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
4215571 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
4215571 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
4215571 | shares |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
240000 | shares |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
160000 | shares |
| CY2022Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
198750 | shares |
| CY2022Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.40 | |
| CY2023 | satt |
Warrants Outstanding Forfeitedcancelled
WarrantsOutstandingForfeitedcancelled
|
-13750 | shares |
| CY2023 | satt |
Average Exercise Price Forfeitedcancelled
AverageExercisePriceForfeitedcancelled
|
2.00 | |
| CY2023 | satt |
Warrants Outstanding Forfeitedcancelled1
WarrantsOutstandingForfeitedcancelled1
|
-66000 | shares |
| CY2023 | satt |
Average Exercise Price Forfeitedcancelled1
AverageExercisePriceForfeitedcancelled1
|
1.50 | |
| CY2023Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
119000 | shares |
| CY2023Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.88 | |
| CY2024Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
119000 | shares |
| CY2024Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.88 | |
| CY2023Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
119000 | shares |
| CY2023Q4 | satt |
Class Of Warrant Or Right Outstanding And Exercisable
ClassOfWarrantOrRightOutstandingAndExercisable
|
119000 | shares |
| CY2024Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
119000 | shares |
| CY2024Q1 | satt |
Class Of Warrant Or Right Outstanding And Exercisable
ClassOfWarrantOrRightOutstandingAndExercisable
|
119000 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
240000 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.7 | |
| CY2023 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
80000 | shares |
| CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.1 | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
160000 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.05 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
0 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
-0 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
0 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
160000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.05 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
160000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.05 | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
536000 | shares |
| CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
5000 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
531000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
531000 | shares |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
203000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
77000 | usd |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
